Skip to main content

Table 2 Association between ERCC1 staining results and prostate cancer clinical characteristics

From: Increased ERCC1 expression is linked to chromosomal aberrations and adverse tumor biology in prostate cancer

 

ERCC1 (%)

  

Parameter

n evaluable

Negative

Weak

Moderate

Strong

p value

All cancers

10,436

35.4

37.1

22.6

5.0

 

Tumor stage

pT2

6790

38.4

37.3

20.1

4.2

<0.0001

pT3a

2299

31.6

35.5

26.4

6.6

pT3b-pT4

1308

26.4

38.8

28.5

6.3

Gleason grade

≤3 + 3

2363

46.3

34.2

16.5

3.0

<0.0001

3 + 4

5630

34.7

37.4

22.9

5.0

3 + 4 Tert.5

368

33.4

40.8

22.0

3.8

4 + 3

1040

25.6

38.8

28.4

7.3

4 + 3 Tert.5

563

23.4

40.0

29.1

7.5

≥4 + 4

466

25.8

38.2

29.0

7.1

Lymph node metastasis

N0

5856

32.7

37.6

23.9

5.8

0.0037

N+

585

25.6

39.8

27.9

6.7

Preoperative PSA level (ng/ml)

<4

1293

32.6

40.5

21.9

4.9

0.0078

4–10

6256

35.2

37.8

22.1

4.8

10–20

2058

37.5

33.9

23.5

5.1

>20

714

35.6

33.9

24.8

5.7

Surgical margin

Negative

8294

36.1

37.5

21.8

4.7

<0.0001

Positive

1953

32.7

35.5

25.9

5.9